These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28247173)

  • 1. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Terawaki H; Hoshi H; Kazama JJ
    Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
    [No Abstract]   [Full Text] [Related]  

  • 2. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
    Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitors of xanthine oxidoreductase].
    Okamoto K
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
    Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
    Sezai A; Obata K; Abe K; Kanno S; Sekino H
    Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
    Ohya M; Shigematsu T
    Clin Exp Nephrol; 2014 Dec; 18(6):835-6. PubMed ID: 24871070
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
    Cicero AFG; Fogacci F; Cincione RI; Tocci G; Borghi C
    Med Princ Pract; 2021; 30(2):122-130. PubMed ID: 33040063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Hisamichi M; Hirata K; Kimura K; Shibagaki Y
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1366-76. PubMed ID: 27029427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
    Tani S; Nagao K; Hirayama A
    Clin Drug Investig; 2015 Dec; 35(12):823-31. PubMed ID: 26482071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
    Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M; Cicero AFG; Borghi C
    Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
    Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
    Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
    J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.